BLISSGVSPharmaceuticals
Bliss GVS Pharma Ltd — Cash Flow Statement
₹215.59
-3.69%
Bliss GVS Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 29.63 Cr | 74.49 Cr | -59.49 Cr | 61.48 Cr | — |
| Repayment Of Debt | -71.75 Cr | -24.38 Cr | -53.90 Cr | -26.36 Cr | — |
| Issuance Of Debt | 55.27 Cr | 15.49 Cr | 40.02 Cr | 10.76 Cr | — |
| Issuance Of Capital Stock | 2.89 Cr | 2.31 Cr | 2.04 Cr | 2.28 Cr | — |
| Capital Expenditure | -76.29 Cr | -28.33 Cr | -93.80 Cr | -74.00 Cr | — |
| End Cash Position | 23.82 Cr | 23.59 Cr | 25.01 Cr | 21.99 Cr | — |
| Beginning Cash Position | 23.59 Cr | 25.01 Cr | 21.99 Cr | 13.13 Cr | — |
| Effect Of Exchange Rate Changes | 0.10 Cr | -0.15 Cr | 1.40 Cr | -9.92 Cr | — |
| Changes In Cash | 0.13 Cr | -1.27 Cr | 1.62 Cr | 18.78 Cr | — |
| Financing Cash Flow | -30.34 Cr | -20.89 Cr | -24.94 Cr | -23.73 Cr | — |
| Interest Paid Cff | -6.82 Cr | -6.10 Cr | -6.30 Cr | -2.96 Cr | — |
| Cash Dividends Paid | -5.45 Cr | -5.39 Cr | -5.44 Cr | -5.33 Cr | — |
| Common Stock Dividend Paid | -5.45 Cr | -5.39 Cr | -5.44 Cr | -5.33 Cr | — |
| Net Common Stock Issuance | 2.89 Cr | 2.31 Cr | 2.04 Cr | 2.28 Cr | — |
| Common Stock Issuance | 2.89 Cr | 2.31 Cr | 2.04 Cr | 2.28 Cr | — |
| Net Issuance Payments Of Debt | -16.47 Cr | -8.90 Cr | -13.87 Cr | -15.61 Cr | — |
| Net Long Term Debt Issuance | -16.47 Cr | -8.90 Cr | -13.87 Cr | -15.61 Cr | — |
| Long Term Debt Payments | -71.75 Cr | -24.38 Cr | -53.90 Cr | -26.36 Cr | — |
| Long Term Debt Issuance | 55.27 Cr | 15.49 Cr | 40.02 Cr | 10.76 Cr | — |
| Investing Cash Flow | -75.44 Cr | -83.19 Cr | -7.75 Cr | -92.98 Cr | — |
| Net Other Investing Changes | 0.02 Cr | 0.02 Cr | 77.58 Cr | -23.69 Cr | — |
| Interest Received Cfi | 16.44 Cr | 5.01 Cr | 13.23 Cr | 5.89 Cr | — |
| Dividends Received Cfi | 0.00 | 0.00 | 5000.00 | 0.00 | — |
| Net Investment Purchase And Sale | -19.02 Cr | -60.49 Cr | 72.12 Cr | -25.93 Cr | — |
| Sale Of Investment | 39.53 Cr | 54.72 Cr | 79.83 Cr | 0.00 | — |
| Purchase Of Investment | -58.55 Cr | -115.21 Cr | -7.71 Cr | -25.93 Cr | — |
| Net Intangibles Purchase And Sale | -0.22 Cr | 0.00 | — | — | — |
| Purchase Of Intangibles | -0.22 Cr | 0.00 | — | — | — |
| Net PPE Purchase And Sale | -72.65 Cr | -27.73 Cr | -93.11 Cr | -72.94 Cr | — |
| Sale Of PPE | 3.41 Cr | 0.60 Cr | 0.69 Cr | 1.07 Cr | — |
| Purchase Of PPE | -76.07 Cr | -28.33 Cr | -93.80 Cr | -74.00 Cr | — |
| Operating Cash Flow | 105.91 Cr | 102.82 Cr | 34.31 Cr | 135.48 Cr | — |
| Taxes Refund Paid | -36.64 Cr | -34.85 Cr | -44.56 Cr | -33.94 Cr | — |
| Change In Working Capital | -51.46 Cr | -46.57 Cr | -85.12 Cr | 73.37 Cr | — |
| Change In Other Current Liabilities | -5.25 Cr | 14.15 Cr | -2.95 Cr | -5.59 Cr | — |
| Change In Other Current Assets | 18.72 Cr | 33.45 Cr | -24.52 Cr | -31.58 Cr | — |
| Change In Payable | 10.84 Cr | -25.10 Cr | -6.32 Cr | 18.34 Cr | — |
| Change In Inventory | -30.45 Cr | -22.42 Cr | 15.00 Cr | -29.10 Cr | — |
| Change In Receivables | -45.31 Cr | -46.65 Cr | -66.34 Cr | 121.29 Cr | — |
| Other Non Cash Items | -8.62 Cr | -5.39 Cr | -3.76 Cr | -4.08 Cr | — |
| Stock Based Compensation | 4.14 Cr | 3.82 Cr | 3.90 Cr | 5.71 Cr | — |
| Provisionand Write Offof Assets | 12.41 Cr | 14.76 Cr | 20.72 Cr | 5.95 Cr | — |
| Depreciation And Amortization | 29.42 Cr | 26.38 Cr | 18.67 Cr | 17.33 Cr | — |
| Amortization Cash Flow | 0.10 Cr | 0.12 Cr | 0.16 Cr | — | — |
| Depreciation | 29.32 Cr | 26.26 Cr | 18.51 Cr | 17.33 Cr | — |
| Pension And Employee Benefit Expense | 3.33 Cr | 1.11 Cr | 0.85 Cr | 1.08 Cr | — |
| Gain Loss On Investment Securities | -0.49 Cr | — | -5000.00 | — | — |
| Net Foreign Currency Exchange Gain Loss | -3.75 Cr | -22.17 Cr | 9.62 Cr | -3.88 Cr | — |
| Gain Loss On Sale Of PPE | 0.49 Cr | -0.29 Cr | -0.37 Cr | -0.14 Cr | — |
| Net Income From Continuing Operations | 125.64 Cr | 146.07 Cr | 106.07 Cr | 127.76 Cr | — |
| Net Other Financing Charges | — | 0.04 Cr | — | — | -5.55 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Bliss GVS Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.